June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

OST-HER2 has received Rare Pediatric Disease Designation for osteosarcoma from the FDA. If it receives a conditional BLA via Accelerated Review before September 30, 2026, it will become eligible for a ...

In a large Chinese trial presented at the American Society of Clinical Oncology annual meeting, neoadjuvant therapy with a ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...